Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2

US10112955B2 · kind B2 · utility

Assignee

• eFFECTOR Therapeutics Inc. · US

Inventors

• Paul A. Sprengeler · San Diego, US
• Siegfried H. Reich · San Diego, US
• Justin T. Ernst · San Diego, US
• Stephen E. Webber · San Diego, US
• Mike Shaghafi · San Diego, US
• Douglas E. Murphy · San Diego, US
• Chinh Viet Tran · San Diego, US

Key dates

• Filing date: Oct 28, 2016
• Grant date: Oct 30, 2018
• Expiry date: Oct 28, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/107
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.